The long-term outcome of graft failure after allogeneic stem cell transplantation (SCT) has not been well described. To fill this knowledge gap we performed a retrospective analysis of patients with graft failure over a 10-year time period in a single institution. Cases were included for analysis if they had failed to achieve an absolute neutrophil count (ANC) of 500/mL or more by 28 days post-SCT or 42 days after cord blood transplantation (primary graft failure); had a decrease in their ANC to \500/mL for 3 consecutive days after having achieved neutrophil engraftment (secondary graft failure); or failed to have evidence of at least 5% or more donor cell engraftment (primary graft failure with autologous reconstitution). Among 1726 patients who underwent allografts from January 1, 1990, through December 31, 2000, we identified 68 patients with graft failure. The 1-, 2-, and 5-year overall survival (OS) for all patients was 31%, 24%, and 15%. A diagnosis of acute leukemia was a significant predictor for poor survival on multivariate analysis. We conclude that graft failure is an uncommon complication postallogeneic SCT, and is associated with poor outcomes. Collection of autologous stem cells prior to high-risk allografting can salvage a fraction of patients and lead to prolonged survivals.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (SCT) is being increasingly employed as treatment for a variety of malignant and nonmalignant hematologic disorders [1] . Allogeneic SCT is used to rescue patients from the myeloablative effects of high-dose pretransplant conditioning therapy. Failure to achieve sustained donor hematopoietic cell engraftment although rare is a life-threatening complication. Various factors such as intensity of the preparative regimen, cell dose, cell manipulation (ie, T cell depletion), prophylaxis used for prevention of graft-versus-host disease (GVHD), human leukocyte antigen (HLA) compatibility, toxicities from infections, and administration of drugs that could damage the allograft have all been identified as interfering with effective and sustained reconstitution of hematopoiesis [2, 3] .
Historically graft failure was a common cause of treatment failure for patients undergoing allogeneic transplants for severe aplastic anemia [4, 5] . Graft failure in this setting was thought to result from low cell doses, relatively low intensity of the conditioning regimen, and allosensitization of the recipients [5] . Improvements in the conditioning regimen, better understanding of graft cell dose and composition, and availability of high-resolution HLA matching techniques have reduced graft failure rates, but have not affected recovery from this complication. Treatment strategies of graft failure have generally revolved around retransplantation and hematopoietic growth factors; however, the efficacy and long-term outcomes of these strategies have not been well described [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] .
The advent of nonmyeloablative and reducedintensity regimens has also changed the transplant paradigm. In this setting it is possible to have relatively normal hematopoietic function after transplant without ever having evidence of donor cell engraftment (primary graft failure with autologous reconstitution). Thus, graft failure in this situation would not result in poor hematopoietic function, but could result in a high rate of disease recurrence because of the loss of the graft-versus-tumor (GVT) effect [19] .
To determine the long-term outcomes of patients with graft failure after allogeneic transplantation, as well as to define prognostic factors for outcomes and describe the results of different interventions, we performed a retrospective analysis of patients with graft failure over a 10-year time period in our institution. The results of this analysis are described herein.
PATIENT AND METHODS
A retrospective chart review and waiver of informed consent was approved by the institutional review board at M.D. Anderson Cancer Center. A database review was conducted to identify cases of graft failure among allograft recipients within the dates of January 1, 1990 , and December 31, 2000. Cases were included regardless of the underlying diagnosis, disease status prior to transplant, preparative regimen, or stem cell source. A patient was considered to have graft failure if any of these 3 conditions were met: (1) primary graft failure: failure to achieve an absolute neutrophil count (ANC) of .500/mL by 28 days after bone marrow (BM) or peripheral blood progenitor cell (PB) transplantation or 42 days after cord blood (CB) transplantation, (2) secondary graft failure: loss of neutrophil engraftment as determined by an ANC of \500/mL for 3 consecutive days after having achieved neutrophil engraftment with documented donor cell chimerism and no evidence of disease progression in the marrow, or (3) primary graft failure with autologous reconstitution defined as achievement of an ANC of at least 500/mL but without evidence of at least 5% or more donor cell chimerism as defined by cytogenetics or molecular techniques [20] . Actuarial survival was estimated by the KaplanMeier methods and compared according to patients' and transplant characteristics using Cox's proportional hazards model; P values of .05 or less were considered statistically significant [21, 22] . For the purpose of this analysis a reduced intense regimen was defined using the criteria established by Champlin et al. [19] .
RESULTS

Incidence and Characteristics of Graft Failure
From a total of 1726 allogeneic transplants performed in our institution between January 1, 1990, and December 31, 2000, (1008 BM, 681 PB, and 37 CB) a total of 68 patients were identified as having either primary or secondary graft failure. Patient characteristics are summarized in Table 1 . Twenty-nine (43%) patients experienced primary graft failure, 30 (44%) secondary graft failure, whereas 9 (13%) had primary graft failure with autologous reconstitution. The most common assigned cause of graft failure was rejection (48%), followed by infection (22%) and persistent disease (19%). Ten patients received no specific therapy for graft failure, 19 patients received growth factors alone (13 of which had secondary graft failure), and 10 patients had autologous cells infused, whereas 29 had cells from a donor of which 26 were procured from the original donor and 3 from a different donor. Seventeen patients were reconditioned prior to reinfusion of donor hematopoietic cells.
Resolution of Graft Failure
Of the 59 patients who developed neutrophil counts of \500/mL, 38 (64%) had neutrophil recovery at a median time of 22 days from the time of graft failure diagnosis (range: 8-86 days). Probability of neutrophil recovery was higher for patients with secondary graft failure (70%) than for those with primary graft failure (59%), but this difference was not statistically significant. The probability of neutrophil recovery was similar for patients receiving growth factor therapy compared to those receiving some form of cellular therapy (67% versus 53%).
Overall Survival
The 1-, 2-, and 5-year overall survival (OS) for all patients was 31%, 24%, and 15%, respectively. Univariate analysis of patient, disease, and transplant characteristics associated with survival are summarized in Table  2 . A diagnosis of acute leukemia and advanced disease (acute leukemia either not in remission or beyond second remission, accelerated phase chronic myelogenous leukemia (CML) or chemorefractory lymphoid malignancy) were the only significant predictors of outcome on univariate analysis with hazard ratios (HRs) of 1.9 and 2.9, respectively (P values of .02 and .006). Of these factors, only a diagnosis of acute leukemia remained significant on multivariate analysis (HR 5 2.6, P 5 .01).
Outcomes According to Type of Graft Failure
Patients with primary graft failure with autologous reconstitution had a longer median survival than those with primary or secondary graft failure (13.7, 2.9, and 3.7 months, respectively, P \ .05). However, 5-year OS rates were similar for all types of graft failure with 18%, 11%, and 13% of patients expected to be alive with primary graft failure, primary graft failure with autologous reconstitution, and secondary graft failure, respectively. Most common causes of death were original malignancy (41%), infection (27%), and graft failure (18%).
Primary graft failure. Twenty-nine patients had primary graft failure, attributed to graft rejection in 18 patients, persistent disease in 7 patients, infection in 3 patients, and an unknown etiology in 1 patient. Five patients had no specific therapy for graft failure; 1 of those patients eventually engrafted with donor cells and died 14 months posttransplant from disease recurrence. The other 4 patients died within 3 months of initial transplantation either from disease progression or infectious complications. Seven patients received previously cryopreserved, autologous stem cells as treatment for their graft failure, 6 had autologous recovery, and 1 died 14 days postinfusion without signs of neutrophil recovery. Five patients were treated with growth factors alone and only 1 achieved neutrophil recovery with autologous reconstitution, resulting in a 221 month survival. The other 4 patients died within 3 months of the original transplant. Five patients received cells from the original donor without preceding chemotherapy, 4 of which had neutrophil recovery with donor cell engraftment. The fifth patient died from progressive disease without hematologic recovery. All 5 patients died from either GVHD, infection, or progressive disease within 8 months of original transplantation (range: 2-8 months).
Seven patients were retransplanted with an allogeneic donor; 6 of those received cells from the original stem cell donor and 1 from an alternate donor. Four of these had donor cell engraftment, 1 had autologous reconstitution, and 2 patients died without neutrophil recovery. Only 2 of these patients survived more than 5 months, 1 died at 20 months from complications of GVHD, and the patient with autologous reconstitution remains alive with active CML at the time of last follow up 721 months posttransplant.
The median survival for patients with primary graft failure in this analysis was 2.9 months posttransplant (range: 0.8-721 months). The outcomes of these patients according to treatment of graft failure is summarized in Figure 1a . Primary graft failure with autologous reconstitution. Nine patients had primary graft failure with autologous reconstitution; 7 of these were after reduced-intensity conditioning (RIC) regimens and 2 after full-dose conditioning. In 5 patients the cause of graft failure was ascribed to rejection, whereas in 4 it was ascribed to persistent disease. Six patients received subsequent stem cell infusions from the same donor with (n 5 4) or without (n 5 2) prior chemotherapy. Two patients received no therapy for graft failure, while another received growth factors alone. The median survival of these patients was 13.7 months (range: 
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4-931 months)
. One patient with CML remains alive in hematologic and cytogenetic remission on imatinib therapy 931 months postinitial transplant. Secondary graft failure. Thirty patients had secondary graft failure, 9 because of rejection, 12 because of infection, and 9 because of other causes (GVHD, drugs, and persistent disease). The median time to secondary graft failure was 51 days (range: 14-356 days). Thirteen patients received treatment with growth factor alone. Twelve of these patients had recovery of graft function, of which 3 were autologous, 8 were donor derived, and 1 was unknown. Three patients remain alive at 581, 631, and 741 months.
Five patients received allogeneic stem cells from the same donor without prior chemotherapy, only 2 of these patients recovered with donor cells, and none survived for more than a year. Four patients were retransplanted with the same donor; 2 engrafted with donor cells, and 1 had autologous reconstitution only after previously cryopreserved, autologous stem cells were infused; all of these patients died between 2 and 4 months of initial transplant. Three patients received an infusion of their previously cryopreserved autologous cells; 1 patient had autologous recovery and died 13 months later from disease progression, whereas 2 patients died before neutrophil recovery could occur 2 and 6 days after the autologous stem cell infusion. Two patients were retransplanted with an alternate donor; 1 recovered with autologous hematopoiesis and is alive 771 months postinitial transplant and the other had donor cell engraftment and died 25 months postinitial transplant from complications of GVHD. The median survival for all patients with secondary graft failure was 3.7 months (range: 0.9-771 months).Only 4 patients remain alive at 581, 631, 741, and 771 months postinitial transplant. Outcomes of patients with secondary graft failure according to treatment are summarized in Figure 1b .
Patients with primary graft failure with autologous reconstitution had a longer median survival than those with primary or secondary graft failure (13.7, 2.9, and 3.7 months, respectively). However, the 5-year OS rates were similar for all types of graft failure with 18%, 11%, and 13% of patients expected to be alive with primary graft failure, primary graft failure with autologous reconstitution, and secondary graft failure, respectively. Most common causes of death were graft failure (18%), infection (27%), or original malignancy (41%). Kaplan-Meier survival curves according to graft failure type and treatment are shown in Table 3 and Figure 2A and B.
DISCUSSION
Graft failure has traditionally been viewed as a complication of allogeneic transplants for aplastic anemia (AA) patients who had received multiple prior transfusions, or for patients receiving T cell-depleted transplants [23] . However, with the advent of unrelated donor transplantation and particularly before modern allele typing, alternative donor transplantation with or without T cell depletion became the most common situation associated with graft failure, occurring in up to 14% of patients in the initial National Marrow Donor Program experience [24] . Improved tissue typing techniques as well as improvements in conditioning and patient selection have reduced the risk of graft failure, but this still represents an important complication of allografting particularly after alternative donor transplantation [24] . The optimal therapy for patients who develop graft failure has not been defined, and a variety of approaches from growth factors to retransplantation have been proposed [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . To develop a rationale approach for the management of this potentially lifethreatening complication we performed a retrospective review of treatment outcomes among 68 patients who developed this complication during a 10-year period in our institution. This retrospective analysis confirmed that graft failure is a relatively rare complication (only 68 cases among 1726 transplants). Notwithstanding, graft failure was still associated with poor outcomes despite successful recovery of hematologic function.
Of particular interest in this retrospective review was the natural history of patients developing graft failure after RIC or truly nonablative regimens. It was initially thought that these patients would have autologous reconstitution if donor cell engraftment did not occur [25] . Twenty-three of the 68 patients with graft failure in this analysis had been conditioned with either an RIC (n 5 7) or a truly nonablative regimen (n 5 16). Of these, 7 died without ever having recovered hematologic function between 0 and 173 days postdiagnosis of graft failure. These results underscore that in patients undergoing RIC who fail to engraft or lose graft function, aggressive treatment of graft failure should be implemented, because autologous reconstitution is far from certain.
Seven of the 8 patients surviving 5 years or more had autologous hematopoietic recovery, 3 of them because of infusion of previously cryopreserved autologous stem cells. This observation confirms the report by Mehta et al. [9] , and underscores the importance of autologous stem cell cryopreservation for patients at high risk for graft failure because of stem cell source or graft manipulation (ie, alternative donor transplants or T cell depletion). Five of these patients were still alive at last follow-up (631, 711, 721, 771, and 931 months after initial transplant). Three of these patients had CML, 1 had AA, and interestingly, 1 patient with refractory acute myelogenous leukemia (AML) remains alive with normal hematologic parameters despite autologous reconstitution with significant cytogenetic abnormalities 741 months after initial transplant. This long-term remission of a patient with a refractory hematologic malignancy despite absence of detectable donor cells has been observed by other investigators and suggests that a GVT effect may be operative at levels below our current limit of detection of donor cells [26, 27] .
This 10-year experience suggests that an aggressive approach to patients with graft failure will be needed to improve outcomes. This begins by identifying patients at high risk for this complication and developing strategies for early intervention. This retrospective experience supports the recommendation that patients with indolent diseases and patients with acute leukemia in remission should have autologous stem cells cryopreserved if they are to undergo an allogeneic transplant with an alternative source of stem cells (ie, mismatched or CB transplants) or cells that are to be manipulated. Seven of the 10 patients who received cryopreserved autologous stem cells for treatment of graft failure had neutrophil recovery and had a median survival of 21 months. Because of the retrospective nature of this review, we were unable to determine why certain patients received certain therapies for graft failure (ie, infusion of cells with or without preceding chemotherapy, use of alternate donor, etc). In this regard, various reports have appeared demonstrating that immunosuppressive conditioning is effective in securing donor cell engraftment in the setting of graft failure with good tolerance and efficacy [13] [14] [15] [16] [17] .
During the initial years of this analysis no intervention was planned until after day 28 when a BM aspirate confirmed lack of donor cell engraftment. We now recommend intervening as soon as it seems likely that delayed hematologic recovery or graft failure may occur (usually 3 weeks after transplant). Initial interventions include: (1) reassessment of all ongoing medications to eliminate all nonessential potentially stem cell toxic drugs (ie, linezolid, acyclovir, ganciclovir, and so forth), (2) early assessment of BM aspiration looking for persistent disease or viral infections (ie, HHV6, parvovirus, CMV, and so forth), (3) institution of intensive growth factor therapy if this has not begun already, and (4) establishing a definitive plan if hematologic recovery has not been achieved by 28 days posttransplant (ie, infusing cryopreserved autologous stem cells, contacting the original stem cell donor or an alternative donor to procure additional stem cells, assessment for investigational strategies, etc.) [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] 29] . The issue of early identification and intervention has also been addressed by Mehta et al., who have recommended considering interventions in patients who have not achieved a peripheral blood leukocyte count of .200/mL by day 16 post-SCT [28] . Retransplantation using novel immunosuppressive regimens can be successful in achieving donor cell engraftment and can be associated with long-term disease control [6] [7] [8] [9] [10] [12] [13] [14] [15] [16] [17] [18] .
CB transplantation is being used increasingly in adults, and is associated with a higher risk of graft failure than BM or peripheral blood SCT. Chan et al. [15] recently reviewed their experience with graft failure after 864 G. Rond on et al.
